Reforms In China's Center For Drug Evaluation Designed To Boost Innovation - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Ongoing reforms in China's drug review body are attracting the attention of the pharma industry, which is hoping the changes will result in a faster drug review process. During the third annual DIA China meeting in Beijing, officials from China's Center for Drug Evaluation unveiled more details of the reform and reaffirmed that the ultimate goals are to improve quality and drive efficiency of drug reviews
You may also be interested in...
China Issues New Guidelines On Phase I Trials – Will It Speed Up Approvals?
The clinical trial process has become a bottleneck for licensing new drugs in China. Now, China’s State FDA has stepped up with a new guideline for Phase I clinical trials– will it help speed up the process?
China State FDA Urges Manufacturers To Abandon Some Projects Ahead Of GMP Implementation - DIA China Conference
BEIJING - China's new good manufacturing practices guidelines for pharmaceuticals officially came into effect March 1, and China's State FDA is now trying to educate domestic companies on how they can implement the new standards. One bit of advice being offered is: "Give up.
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process